Siponimod-associated cystoid macular edema without known risk factors
Open Access
- 22 July 2024
- journal article
- case report
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 36, 102124
Abstract
No abstract availableKeywords
Funding Information
- Research to Prevent Blindness
- National Eye Institute
This publication has 14 references indexed in Scilit:
- Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical reviewAnnals of Clinical and Translational Neurology, 2024
- Macular edema after siponimod treatment for multiple sclerosis: a case report and literature reviewBMC Neurology, 2023
- Siponimod-Related Bilateral Macular Edema: A Transient and Completely Reversible DisorderJournal of Neuro-Ophthalmology, 2023
- Siponimod-related bilateral cystoid macular oedema and intravenous fluorescein angiographic findings in a patient with stable proliferative diabetic retinopathy without history of diabetic macular oedemaBMJ Case Reports, 2022
- Siponimod associated macular edema in a patient with multiple sclerosisNeuroimmunology Reports, 2021
- Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple SclerosisDrugs, 2021
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 studyThe Lancet, 2018
- Sphingosine 1-Phosphate Receptor Modulators in Multiple SclerosisCNS Drugs, 2015
- Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 studyThe Lancet Neurology, 2013
- Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple SclerosisOphthalmology, 2013